top of page

ComPareNET: Lu-177 DOTATATE vs CAPTEM in Advanced pNETs

Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu-177 Dotatate in Patients with Advanced Pancreatic Neuroendocrine Tumors


DRUG/TREATMENT: Lutetium Lu-177 Dotatate PRRT (Peptide Receptor Radionuclide Therapy) versus CAPTEM (Capecitabine and Temozolomide) 


STATUS: Recruiting

SPONSOR: Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)

Dr. Heloisa Soares Discusses ComPareNET: Lu-177 DOTATATE vs CAPTEM


This phase II trial compares capecitabine and temozolomide to lutetium Lu-177 dotatate for the treatment of pancreatic neuroendocrine tumors that have spread to other parts of the body (advanced) or are not able to be removed by surgery (unresectable). Chemotherapy drugs, such as capecitabine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radioactive drugs, such as lutetium Lu-177 dotatate, may carry radiation directly to tumor cells and may reduce harm to normal cells. The purpose of this study is to find out whether capecitabine and temozolomide or lutetium Lu-177 dotatate may kill more tumor cells in patients with advanced pancreatic neuroendocrine tumors.

For more information on eligibility criteria, trial locations, study details, etc., go to to view this trial here.


This is a multicenter trial with various locations. Go to the “Contacts and Locations” section of this trial page at for site-specific contact information.

bottom of page